Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“Prof. Myriam Chalabi cancer immunotherapy expert at The Netherlands Cancer Institute
Beyond MSI High!!!
Very cool! Saw a response in Undifferentiated pleiomorphic sarcoma – see scans.
Key take-aways:
- Short course neoadjuvant ICB is extremely effective in dMMR colon cancers and is associated with excellent long-term outcomes
- Optimal combinations, duration of treatment and organ preservation
- ICB is effective in a subgroup of pMMR colon cancers
- Validation of potential predictive (attainable) biomarkers in future trials
- Additional avenues
modulation
Chemotherapy
Targeting
Immunosuppression
Novel treatments - Potential neoadjuvant ICB in non-CRC dMMR and pMMR tumors ongoing.”
More posts featuring Bernard A. Fox.
